Orexigen Partners With Takeda To Commercialize Obesity Drug Contrave (Naltrexone SR/Bupropion SR)

Friday, September 3rd, 2010

Contrave (naltrexone SR/bupropion SR), an investigational drug aimed at combination therapy to address both biological and behavioral drivers of obesity, will be developed and commercialized by Orexigen Therapeutics, Inc. and Takeda Pharmaceutical Company Limited in the USA, Canada and Mexico. The two drug firms have just signed an exclusive partnership ...

Foundation Names UIC Educator As Nurse Faculty Scholar

Wednesday, September 1st, 2010

Shannon Zenk, assistant professor of health systems science at the University of Illinois at Chicago, was one of 12 nurse educators nationwide selected as a Nurse Faculty Scholar by the Robert Wood Johnson Foundation. The three-year, $350,000 grant is presented to junior faculty members who show outstanding promise as future ...

California Obesity Epidemic on the Rise

Tuesday, August 31st, 2010

In California, approximately three in five adults, one in three teens and one in nine children are overweight or obese. That translates to obesity affecting a majority of all the adults and almost 1,000,000 children living in the state, a state full of sunshine, hiking paths, and city parks; a ...

Oesophageal cancer rates rise steeply in men

Saturday, August 28th, 2010

Rates of oesophageal cancer in men have risen by 50 percent in Britain in a generation, an increase that is probably being driven in part by growing rates of obesity and poor diet, scientists said on Saturday. Find more info about Oesophageal cancer rates rise steeply in men photos videos pictures. ...

Esophageal cancer rates rise steeply in British men

Saturday, August 28th, 2010

Rates of esophageal cancer in men have risen by 50 percent in Britain in a generation, an increase that is probably being driven in part by growing rates of obesity and poor diet, scientists said on Saturday. Find more info about Esophageal cancer rates rise steeply in British men photos videos ...